Table of Contents
How much do Biologics cost in India?
“Biologics are expensive. The treatment cost for biologics ranges from Rs300,000 to Rs600,000 per annum. Oral tablets are relatively much cheap. Safety profile of apremilast is established through clinical trials and post marketing survey abroad but we will get more clarity once it starts getting prescribed in India.
Is there any ayurvedic treatment for ankylosing spondylitis?
Ankylosing spondylitis (AS) is a rheumatic disease with various skeletal and extra skeletal manifestations. No satisfactory treatment is available in modern medicine for this disorder. Various Panchakarma procedures and Ayurvedic drugs have been proved useful for these manifestations.
Is there any treatment for ankylosing spondylitis in Ayurveda?
Are biologics covered by insurance in India?
There are no controlled trials or case series on the use of biologics in India, though they are being used. Being a resource poor country and with no insurance coverage for the use of biologics, we find that while there is a need for guidelines, there is no sifficient Indian data to rely upon.
What is ankylosing spondylitis (AS)?
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that commonly affects the spine, although other joints in the body may also be affected. AS causes pain and stiffness, and as the condition progresses, the joints may fuse, causing lack of flexibility and mobility.
What are biologics for spondylitis?
Biologics are also typically used in people with AS who have evidence of joint damage visible on imaging (radiographic axial spondylitis). 1 Biologic therapies are complex molecules made from living organisms, and the sources used may be human, animal, bacteria, or yeast.
Are women more prone to radiographic spondylitis?
Although women had less severe radiological involvement of the thoracic and lumbar spine as evidenced by lower Bath Ankylosing Spondylitis Radiology Index (BASRI) scores [ 35 ], when adjustment was made for radiographic spinal damage, they were found to have reported worse functional outcomes than men at any given level of radiographic damage.